Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 9,409

Document Document Title
WO/2022/196634A1
An organic electroluminescent element (1) which comprises a positive electrode (3), a negative electrode (4), and a light emitting layer (5) that is interposed between the positive electrode (3) and the negative electrode (4), wherein: t...  
WO/2022/193871A1
The present invention relates to a KRASG12D inhibitor and the use thereof, and in particular, provided is a compound as shown in a formula (I), wherein each substituent in the formula is defined in the description. Furthermore, the prese...  
WO/2022/194779A1
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2), methods of preparing such compounds, pharmaceutical compositions contain...  
WO/2022/197756A1
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.  
WO/2022/194267A1
A GPR84 antagonist, and a preparation method therefor and a use thereof, specifically a compound represented by formula (I), and a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof. The compou...  
WO/2022/194192A1
The present invention relates to a compound represented by formula I or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound or a metabolite thereof, a pharmaceut...  
WO/2022/197913A1
This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB1) an...  
WO/2022/194781A1
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions contain...  
WO/2022/194066A1
Provided are a compound having KRAS G12D modulating activity, a preparation method for same, and a pharmaceutical composition comprising same.  
WO/2022/194906A1
The present invention relates to the compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.  
WO/2022/196528A1
A compound which is represented by formula (I) or a salt thereof. In addition, a herbicide which contains, as an active ingredient, at least one substance that is selected from among the above-described compound and salt. In the formula ...  
WO/2022/194909A2
The present invention relates to a process for the preparation of 7-(4,7- diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyri dazin-6-yl)pyrido[1,2- a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.  
WO/2022/187965A1
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, c...  
WO/2022/188792A1
The present invention relates to a compound of formula (I), a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof for preventing or treating tumor-related diseases or conditions.  
WO/2022/192145A1
One embodiment of the disclosureis a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat...  
WO/2022/188802A1
Provided is a use of Wee1 kinase inhibitors in the treatment of cancer. In particular, provided is a use of Wee1 kinase inhibitors in the preparation of drugs for the treatment of cancers with Histone H3K27M mutation.  
WO/2022/188823A1
The present invention relates to the technical field of medicines, and in particular to a tricyclic HPK1 inhibitor compound or a pharmaceutically acceptable salt or stereoisomer thereof, a pharmaceutical composition and a preparation con...  
WO/2022/190626A1
The problem to be solved by the present invention is to provide novel organic nano-particles and a novel compound for constituting the organic nano-particles. The present invention provides a compound represented by general formula (1) o...  
WO/2022/187964A1
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, c...  
WO/2022/187856A1
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.  
WO/2022/187588A1
The present disclosure relates to compounds of Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X, J, Y, Z, n, and B1 are as defined as set forth in the specification. The present disclosure also rela...  
WO/2022/184178A1
Provided are KRAS G12D inhibitors of formula (I) or formula (IV), a composition containing the inhibitor and the use thereof.  
WO/2022/187520A1
The invention provides substituted 3-piperidinyl-pyrazolo[3,4-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.  
WO/2022/187518A1
The invention provides substituted 4-pipcridinyl-imidazo[4,5-b]pyridincs and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.  
WO/2022/182415A1
The present disclosure provides compounds of Formula I, methods of preparing the compounds, compositions, kits, and methods of using the compounds for treating or preventing microbial infections.  
WO/2022/180397A1
Pharmaceutical Compounds Benzodiazepine derivatives of formula (I): wherein: R1 is H or F; R2 is selected from formula (II) and formula (III) R3 is C1-C6 alkyl which is unsubstituted or substituted by CF3, or is a monocyclic 4- to 6-memb...  
WO/2022/182839A1
The present application provides spirocyclic lactam compounds of Formula I that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.  
WO/2022/178256A1
The present disclosure relates compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, ...  
WO/2022/175675A1
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, U, X, Y and B are as define...  
WO/2022/178205A1
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.  
WO/2022/170831A1
The present application belongs to the technical field of organic materials, and provides an organic electroluminescent material, an electronic element and an electronic apparatus. The structure of the organic electroluminescent material...  
WO/2022/171147A1
Provided are pyrimidine aromatic ring compounds. Specifically provided is a compound as represented by formula (II) or a pharmaceutically acceptable salt thereof.  
WO/2022/170737A1
A thienopyrimidine compound (a compound of formula N) and a preparation method therefor. Specifically, the provided preparation method comprises the steps of: (a) in a solvent A, reacting, in the presence of an organic base and acyl chlo...  
WO/2022/173678A1
Provided herein are tetracyclic oxazepinyl compounds useful in the treatment on cancers.  
WO/2022/171143A1
A class of 5,6,7,8-tetrahydropyridine [3,4-d] pyrimidine compounds, specifically a compound as shown in formula (II) or a pharmaceutically acceptable salt thereof.  
WO/2022/171138A1
A crystalline form of a nitrogen-containing heterocyclic compound, a preparation method therefor and an application thereof. A crystalline form A of a compound represented by formula I, displaying a diffraction peak at 5.20±0.2°, 7.30...  
WO/2022/171745A1
The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I), wherein X, Y, R1, R2, R3, R4, R5, R6, R6a are as defined herein, compositions including the compounds, processes of manufacturing t...  
WO/2022/173033A1
[Problem] To provide compounds that are useful as active ingredients of pharmaceutical compositions for the treatment of pancreatic cancer. [Solution] The present inventors studied compounds that are useful as active ingredients of pharm...  
WO/2022/171151A1
The present disclosure relates to an SMTP-7 derivative and the use thereof. In particular, provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the descript...  
WO/2022/171013A1
Disclosed in the present invention is a tetrahydroquinazoline compound. Specifically, disclosed is a compound represented by formula (II) and a pharmacologically acceptable salt thereof.  
WO/2022/173460A1
Novel cinchona alkaloid compounds have been synthesized and discovered to have potent cytotoxic activity against cancer cells both in vitro and in vivo. Cinchona alkaloids, including trimeric cinchona alkaloids as well as their polymers ...  
WO/2022/171166A1
The present invention provides an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present invention also provides a preparation method for such a compound, a composition containing such a co...  
WO/2022/170999A1
A KRAS inhibitor compound as represented by formula (II) or a pharmaceutically acceptable salt thereof.  
WO/2022/174184A1
Compounds are provided according to Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, tautomers and stereoisomers, as well as pharmaceutical compositions, wherein Ring B, Ring A, R1, R2, R6, L, X1 and X2 a...  
WO/2022/169921A1
The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said comp...  
WO/2022/166974A1
A pyridopyrimidinone derivative as represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt thereof or a prodrug thereof. The pyridopyrimidinone derivative has a good SOS1 inhibit...  
WO/2022/169948A1
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...  
WO/2022/166642A1
A nitrogen-containing polycyclic fused ring compound represented by formula I, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. As a highly selective and effective RET inhibitor, the compound has a ...  
WO/2022/167682A1
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).  
WO/2022/168856A1
The present invention provides a photoelectric conversion element that has excellent manufacturing suitability and excellent photoelectric conversion efficiency with respect to light in a wide wavelength range. The present invention also...  

Matches 501 - 550 out of 9,409